Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Oaknin

Showing results (141-150 of 173) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Cancers|June 10, 2023
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO StudyAntonio Fernández-Serra, Raquel López-Reig, Raúl Márquez, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Lancet (London, England)|December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian CarcinomaAmit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Gynecologic Oncology|March 28, 2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trialDomenica Lorusso, Ana Oaknin, Giuliano S Borges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
Pageof 18

Showing results (141-150 of 173) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Cancers|June 10, 2023
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO StudyAntonio Fernández-Serra, Raquel López-Reig, Raúl Márquez, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Lancet (London, England)|December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian CarcinomaAmit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Gynecologic Oncology|March 28, 2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trialDomenica Lorusso, Ana Oaknin, Giuliano S Borges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
Pageof 18